Last reviewed · How we verify
NCT03610815
Community I-STAR Mozambique: Community Implementation of SBIRT Using Technology for Alcohol Use Reduction in Mozambique
Phase 4 trial testing Screening, Brief Intervention, Referral to Treatment in mSBIRT - Mobile Screening, Brief Intervention, Referral to Treatment in 540 participants. Completed in 31 August 2025.
31 August 2025
Quick facts
| Lead sponsor | New York State Psychiatric Institute |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | health services research |
| Enrollment | 540 |
| Start date | 1 October 2021 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 1 location across Mozambique |
Drugs / interventions tested
- Screening, Brief Intervention, Referral to Treatment
Conditions studied
- mSBIRT - Mobile Screening, Brief Intervention, Referral to Treatment — all drugs for mSBIRT - Mobile Screening, Brief Intervention, Referral to Treatment →
- SBIRT-CTS - Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision Strategy — all drugs for SBIRT-CTS - Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision Strategy →
Sponsor
New York State Psychiatric Institute
Who can join
18 and older, any sex, with mSBIRT - Mobile Screening, Brief Intervention, Referral to Treatment or SBIRT-CTS - Screening, Brief Intervention, Referral to Treatment Conventional Training and Supervision Strategy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Hazardous drinking (HD) is a major public health burden worldwide with significant morbidity and mortality. To reduce HD, the World Health Organization (WHO) recommends using Screening, Brief Intervention, Referral to Treatment (SBIRT). Mobile health technology (mHealth), such as the mSBIRT app, is a promising tool for widespread cost-effective delivery of evidence-based HDS by community health workers (CHWs) because of its potential to increase fidelity, effectiveness, and sustainability. Community I-STAR Mozambique comprises three phases: 1) mSBIRT adaptation, 2) a cluster-randomized trial, and 3) scale-up of the most cost-effective intervention. Community I-STAR Mozambique will scale-up a cost effective, sustainable program and inform policy applicable to Mozambique and other LMICs.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Psychosocial and pharmacologic interventions to reduce harmful alcohol use in low- and middle-income countries.
Greene MC, Kane J, Alto M, Giusto A, et al · · 2023 · cited 7× · PMID 37158538 · DOI 10.1002/14651858.cd013350.pub2 -
Scale-Up Study Protocol of the Implementation of a Mobile Health SBIRT Approach for Alcohol Use Reduction in Mozambique.
Suleman A, Mootz JJ, Feliciano P, Nicholson T, et al · · 2021 · cited 6× · PMID 34126774 · DOI 10.1176/appi.ps.202000086
Verify or expand the search:
- PubMed search for NCT03610815
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other New York State Psychiatric Institute trials
Trials by the same sponsor.
- NCT05416658 — Shared Decision Making for Antipsychotic Medications · NA · not yet recruiting
- NCT07423546 — A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia · Phase 1, PHASE2 · not yet recruiting
- NCT05339256 — Sublingual Buprenorphine Through Telemedicine vs In-Person Care as Usual · Phase 2 · not yet recruiting
- NCT05563948 — Repeated Administration of Cannabis Varying in THC and CBD · Phase 2 · suspended
- NCT06977308 — A Multimodal Imaging Study of Dopamine in Early Psychosis · Phase 1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03610815 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by New York State Psychiatric Institute
- Last refreshed: 6 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03610815.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing